AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 126 Posts
1 2 3 ... 8
AstraZeneca's Q1 Earnings & Sales Miss, Stock Down
Article By: Zacks Investment Research Friday, May 18, 2018 12:13 PM EDT
This year so far, AstraZeneca’s shares have risen 5.0% against the industry’s decline of 3.8%.
In this article: AZN Also: LLY, MRK, LGND
Read
Week In Review: $3.4 Billion Week For China Life Science Deals
Article By: ChinaBio® Today Saturday, May 12, 2018 4:50 PM EDT
Armo Biosciences, a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly. Lilly offered to pay $50 per share for Armo, a three-fold increase from the IPO price and a 67% jump from its previous close.
In this article: AZN, LLY, ARMO, GILD
Read
AstraZeneca (AZN) Beats On Q4 Earnings, Guides For 2018
Article By: Zacks Investment Research Friday, February 2, 2018 10:30 AM EDT
AstraZeneca plc reported fourth-quarter 2017 core earnings of 65 cents per American Depositary Share (ADS), which beat the Zacks Consensus Estimate of 45 cents. Core earnings rose 13% year over year at constant exchange rates (CER).
In this article: AZN Also: MRK, INCY, ABBV
Read
3 Large Cap Pharma Stocks To Beat Earnings This Quarter
Article By: Zacks Investment Research Tuesday, January 23, 2018 4:55 PM EDT
The fourth-quarter earnings season is in full swing and the trend so far appears impressive.
In this article: AZN, MRK, ABBV
Read
Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug
Article By: ChinaBio® Today Saturday, January 13, 2018 6:23 PM EDT
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US.
In this article: VRACY, BSTG, VAR, AZN, BMY, AMGN, BGNE
Read
4 Large-Cap Pharma Stocks That Outperformed The S&P This Year
Article By: Zacks Investment Research Sunday, December 31, 2017 2:53 PM EDT
Upbeat quarterly results, rise in demand on new product sales, successful innovation and product line expansion, strong clinical study results as well as strong performance of legacy products propelled the large-cap drug sector to new highs in 2017.
In this article: AZN, JNJ, NVO, ABBV Also: RHHBY
Read
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates From Novartis
Article By: Arpita Dutt Saturday, December 30, 2017 7:49 PM EDT
Key announcements in the pharma space this week include a couple of acquisition announcements and regulatory updates from Novartis.
In this article: AGN, AZN, BMY, GSK, NVS, RHHBY, MNK
Read
Week In Review: Walgreens Boots Alliance Spends $420 Million For China Pharmacy Presence
Article By: ChinaBio® Today Saturday, December 2, 2017 4:50 PM EDT
Global retail pharmacy Walgreens Boots Alliance will pay $420 million to acquire a 40% stake in Sinopharm Holding GuoDa Drug Store Co, the largest retail pharmacy chain in China.
In this article: AZN, GSK, GILD, WBA
Read
Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod
Article By: Arpita Dutt Friday, November 10, 2017 3:13 PM EDT
Earnings remained in focus this week with companies like AstraZeneca reporting third-quarter results. Meanwhile, companies like Roche and Merck & Co., Inc. were in the news due to regulatory updates.
In this article: AZN, GSK, MRK Also: JNJ, LLY, SNY, RHHBY
Read
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
Article By: Zacks Investment Research Thursday, November 9, 2017 11:15 AM EDT
AstraZeneca plc reported third-quarter 2017 core earnings of 56 cents per American Depositary Share (ADS), which missed the Zacks Consensus Estimate of 57 cents.
In this article: AZN Also: MRK, JNJ
Read
Week In Review: WuXi AppTec Acquires US-Global Clinical CRO
Article By: ChinaBio® Today Saturday, October 21, 2017 5:25 PM EDT
WuXi AppTec, China's largest CRO/CMO, will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin,Texas. WuXi said the acquisition would extend its CRO network around the world.
In this article: AZN, HCM, RVX, FGEN
Read
AstraZeneca's Asthma Candidate Shows Promising Results
Article By: Zacks Investment Research Tuesday, September 12, 2017 12:33 PM EDT
AstraZeneca Plc. announced a subgroup analysis from SIROCCO and CALIMA phase III studies. The studies revealed the efficacy of benralizumab and also showed that this antibody provides increased benefits to patients.
In this article: AZN Also: SNY, REGN
Read
Astrazeneca, Amgen Phase IIb Trial Of Tezepelumab Met Primary Endpoint
Article By: The Fly Thursday, September 7, 2017 8:20 AM EDT
AstraZeneca and Amgen announced results from the Pathway Phase IIb trial of tezepelumab that they say "showed a significant reduction" in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma.
In this article: AZN, AMGN
Read
AstraZeneca And Takeda Pharmaceutical Company Limited Parkinson's Collaboration
Article By: Samuel Rae Thursday, August 31, 2017 12:48 PM EDT
AstraZeneca announced that it has put together a deal with Takeda Pharmaceutical Company Limited that will see the two collaborate on the development of a brand-new Parkinson's disease asset.
In this article: AZN, TKPYY Also: RHHBY, PRTA
Read
AstraZeneca And Takeda Ink Deal To Develop Parkinson's Drug
Article By: Zacks Investment Research Wednesday, August 30, 2017 3:10 PM EDT
AstraZeneca PLC and Takeda Pharmaceutical Company Limited, a Japanese pharma company, have entered into an agreement to jointly develop and commercialize preclinical candidate MEDI1341.
In this article: AZN Also: RHHBY, ACOR, PRTA
Read
Citi Sees Advantage For Tesaro Despite Broad Lynparza Label
Article By: The Fly Friday, August 18, 2017 6:00 AM EDT
Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's Lynparza increases competition for Tesaro.
In this article: AZN, TSRO Also: CLVS
Read
1 to 16 of 126 Posts
1 2 3 ... 8